Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...
1d
Interferon signal reprograms macrophage mitochondria to promote inflammation resolution, finds study
When our body fights an infection, the immune system must quickly activate defenses and trigger a beneficial inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results